JAMP BISOPROLOL 10 MG
BISOPROLOL FUMARATE : 10 MG · DIN 02518791 · JAMP PHARMA CORPORATION
Health Canada status: MARKETED
What is JAMP BISOPROLOL?
JAMP BISOPROLOL 10 MG contains BISOPROLOL FUMARATE : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02518791, held by JAMP PHARMA CORPORATION, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 18-Mar-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is JAMP BISOPROLOL used for?
Management of patients with mild to moderate hypertension. May be used alone or in combination with other antihypertensive agents, particularly thiazide diuretics.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02518791 |
|---|---|
| Brand name | JAMP BISOPROLOL |
| Generic / active ingredient | BISOPROLOL FUMARATE : 10 MG |
| Manufacturer | JAMP PHARMA CORPORATION |
| Strength | 10 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C07AB07 BISOPROLOL |
| AHFS class | 24:24.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 18-Mar-2022 |
| Original market date | 2022-03-18 00:00:00 |
How is it administered?
Administered orally. For hypertension, may be used alone or with other agents. Dosage should be individualized. Gradual withdrawal over 2 weeks is recommended.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text (refers to STORAGE AND STABILITY section).
How is it supplied?
Not explicitly detailed in the provided text (refers to DOSAGE FORMS, COMPOSITION AND PACKAGING section).
Contraindications
Hypersensitivity; acute heart failure; cardiogenic shock; 2nd/3rd degree AV block; sick sinus syndrome; bradycardia (<60 bpm); hypotension (<100 mmHg); severe asthma/COPD; Raynaud's syndrome.
Warnings and precautions
Do not abruptly discontinue (risk of myocardial infarction/arrhythmia). Caution in heart failure, diabetes (may mask hypoglycemia), thyrotoxicosis, and bronchospastic disease.
What can be used instead?
Other Canadian products sharing ATC code C07AB07 BISOPROLOL. 24 of 52 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-BISOPROLOL | 10 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02521164 |
| AG-BISOPROLOL | 5 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02521156 |
| APO-BISOPROLOL | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02256177 |
| APO-BISOPROLOL | 5 MG | TABLET | APOTEX INC | MARKETED | DIN 02256134 |
| BISOPROLOL | 10 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02391597 |
| BISOPROLOL | 5 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02391589 |
| BISOPROLOL TABLETS | 10 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02495570 |
| BISOPROLOL TABLETS | 5 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02495562 |
| JAMP BISOPROLOL | 5 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02518805 |
| MINT-BISOPROLOL | 10 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | DIN 02465620 |
Who else supplies BISOPROLOL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. BISOPROLOL appears in 699 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.